In silico and *in vitro* analysis of recombinant arginine deiminase from *Pseudomonas furukawaii* as a potential anticancer enzyme

Rakhi Dhankhar

Maharshi Dayanand University Rohtak

Anubhuti Kawatra

Maharshi Dayanand University Rohtak

Vatika Gupta

Jawaharlal Nehru University

Aparajita Mohanty

University of Delhi Gargi college

Pooja Gulati (✉ gulatipooja1@gmail.com)

Maharshi Dayanand University Rohtak <https://orcid.org/0000-0002-3442-5125>

Research Article

Keywords: Arginine deiminase, Anticancer, Mycoplasma hominis, Pseudomonas furukawaii, In silico analysis

Posted Date: January 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1000203/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Arginine deiminase (ADI), a promising anticancer enzyme from *Mycoplasma hominis*, is currently in phase III of clinical trials for the treatment of arginine auxotrophic tumors. However, it has been associated with several drawbacks in terms of low stability at human physiological conditions, high immunogenicity, hypersensitivity and systemic toxicity. In our previous work, *Pseudomonas furukawaii* was identified as a potent producer of ADI with optimum activity under physiological conditions. In the present study, phylogenetic analysis of microbial ADIs indicated *P. furukawaii* ADI (PfADI) to be closely related to experimentally characterized ADIs of *Pseudomonas* sp. with proven anticancer activity. Immunoinformatics analysis was performed indicating lower immunogenicity of PfADI than MhADI (*M. hominis* ADI) both in terms of number of linear and conformational B cell epitopes and T cell epitope density. Overall antigenicity and allergenicity of PfADI was also lower as compared to MhADI, suggesting the applicability of PfADI as an alternative anticancer biotherapeutic. Hence, *in vitro* experiments were performed in which the ADI coding *arcA* gene of *P. furukawaii* was cloned and expressed in *E. coli* BL21. Recombinant ADI of *P. furukawaii* was purified, characterized and its anticancer activity was assessed. The enzyme was stable at human physiological conditions (pH 7 and 37 °C) with K_m of 1.90 mM. PfADI was found to effectively inhibit the HepG2 cells with an IC_{50} value of 0.1950 IU/ml. Therefore, the current *in silico* and *in vitro* studies establish PfADI as a potential anticancer drug candidate with improved efficacy and low immunogenicity.

Highlights

- *In silico* analysis predicted low immunogenicity and allergenicity of PfADI than MhADI
- ADI of *Pseudomonas furukawaii* was cloned and expressed in *E. coli*
- The recombinant PfADI was characterized and found to be stable at physiological conditions
- PfADI was found to effectively inhibit the HepG2 cells with an IC_{50} value of 0.1950 IU/ml

Introduction

Arginine deiminase (ADI, EC 3.5.3.6) is an arginine catabolizing hydrolase that catalyzes the conversion of L-arginine into L-citrulline and ammonia¹. ADI is the major enzyme of the arginine deiminase pathway in prokaryotes that serve as a non-glycolytic pathway for energy generation². Besides energy production and arginine catabolism, ADI also protects the bacteria from acidic environment by generation of ammonia³. The enzyme is widely present in bacteria and few lower protozoa but has not been reported in mammals⁴.

ADI has gained wide importance in the last three decades and emerged as an important therapeutic agent for the treatment of arginine auxotrophic cancers via amino acid deprivation therapy⁵. Arginine is non-essential amino acid for humans (essential for neonates); it is synthesized in the urea cycle with the help of enzymes arginine succinate synthetase (ASS) and arginine succinate lyase (ASL)⁶. However, certain

tumors lack these enzymes and rely on surrounding cells for the supply of amino acid arginine. This difference in physiology of tumor cells from normal cells is harnessed in the treatment of such arginine auxotrophic tumors using ADI. ADI depletes arginine in these tumors and consequently the tumor recedes mainly due to protein starvation ^{7,8}. The ADI also induces both caspase dependent and independent pathways to inhibit the proliferation of tumor cells ^{9,10}.

The anticancer activity of ADI from various microbial sources *viz. Mycoplasma arginini, Mycoplasma hominis, Pseudomonas plecoglossicida, Pseudomonas aeruginosa, Lactobacillus lactis* have been reported earlier ². Currently ADI-PEG (pegylated ADI) from *Mycoplasma* is in the late-stage clinical development for the treatment of hepatocellular carcinoma (HCC), melanoma and mesothelioma (NCT01287585, NCT00450372, NCT02709512). Polaris pharmaceuticals, a leading biopharmaceutical company, holds the world-wide rights for ADI-PEG named Pegargiminase (<http://polarispharma.com/>). In spite of promising preclinical results, the efficacy and safety of *Mycoplasma* ADI is limited due to the immunogenic and allergic reactions. *Mycoplasma* ADI treatment is reported to elicit hypersensitivity reactions ranging from local and systemic allergy to anaphylactic shock ^{11,12}. Although the enzyme is pegylated, PEG has its own limitations and it reduces the overall efficacy of the enzyme. It was observed that drug clearance and toxicity was enhanced due to production of anti-PEG antibodies while using pegylated therapeutic enzymes asparaginase and uricase ^{13,14}. Hence, to circumvent these hurdles, it is of great interest to find a suitable alternative ADI with high activity and low immunogenicity.

With the purpose of identifying potent anticancer ADI, in our previous work, we had screened bacterial isolates from environmental samples and identified *Pseudomonas furukawaii* as an alternate source of ADI with optimum activity at human physiological conditions ¹⁵. In this study, phylogenetic relatedness of PfADI with other microbial ADIs was assessed and the immunoinformatics analysis was carried out to compare the immunogenicity and allergenicity of PfADI with the ADI from *M. hominis* (MhADI) (currently in clinical trial) in order to ascertain the potential of PfADI as an anticancer agent. The 3D structure of the enzymatic protein was also predicted, and the sequence-structure analysis was performed to identify the putative antigenic epitopes. Further in vitro experiments involving cloning and expression of *arcA* gene (gene coding ADI) of *P. furukawaii* in *Escherichia coli* were carried out. The recombinant *P. furukawaii* ADI (rPfADI) was purified, characterized and its *in vitro* anticancer activity was assessed.

Materials And Methods

2.1 *In silico* studies

2.1.1 Sequence based phylogenetic analysis

A total of 1121 sequences of ADI of *Pseudomonas sp* were retrieved from UniProt (<https://www.uniprot.org/>). CD-HIT tool (<http://weizhong-lab.ucsd.edu/cdhit-web-server/>) was used to group similar sequences at 80% similarity cut-off value and 22 clusters were obtained. Representative

sequences of each cluster along with ADI sequences of *M. hominis*, *M. arginini* and PfADI¹⁶ (Accession: BAU77093) (Table S1) were used for phylogenetic tree construction. Neighbor-joining method¹⁷ was employed for tree construction, using MEGA X software¹⁸. Bootstrapping with 1000 replicates was performed¹⁹ and distances were computed using the number of differences method²⁰.

2.1.2 Protein structure prediction of PfADI:

SWISS-MODEL server (<https://swissmodel.expasy.org/>) was used to predict the 3D structure of PfADI (Accession No. BAU77093). The sequence length of PfADI consisted of 416 amino acids. The crystal structure of ADI from *Pseudomonas aeruginosa* (PDB code_2ACI) was used as a template for building the model. The quality of the predicted 3D structure of PfADI was validated by Ramachandran plot obtained for the model (URL: <https://swissmodel.expasy.org/assess>).

2.1.3 Immunoinformatics analysis of PfADI for antigenicity prediction

2.1.3.1 Sequence and structural data: The amino acid sequence of PfADI and its modeled 3-D structure were used for immunoinformatics analysis. MhADI amino acid sequence was retrieved from UniProtKB (<https://www.uniprot.org/uniprot/P41141>) and used for comparative studies.

2.1.3.2 Prediction of antigenicity and allergenicity: The antigenicity was predicted using VaxiJen server (<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>). VaxiJen uses alignment independent approach to predict the antigenicity of the whole protein²¹. The allergenicity prediction was performed using AlgPred (<http://crdd.osdd.net/raghava/algpred/>) server²². The antigenicity and allergenicity of PfADI were compared with MhADI.

2.1.3.3 T-cell epitope prediction: The MHC-II binding T cell epitopes were predicted using Immune Epitope Database (IEDB) server (<http://tools.iedb.org/mhcii/>). The reference alleles were chosen on the basis of their wide global frequency. A total of 8 HLA-DRB1 alleles (*01:01, *03:01, *04:01, *07:01, *08:01, *11:01, *13:01, and *15:01) were used to predict the T cell epitopes^{23,24}. The epitope density was obtained by calculating the relative frequency of the predicted epitopes. Relative frequency (fi)= ni/N, where ni is the number of epitopes within the threshold (percentile values ≤ 10) and N represents the total number of predicted epitopes.

2.1.3.4 B-cell epitope prediction: Linear or continuous B cell epitopes were predicted using BepiPred server (<http://tools.iedb.org/bcell/>). Conformational B cell epitopes were predicted using modeled PfADI 3D structure. BEpro (previously known as PEPITO) (<http://pepito.proteomics.ics.uci.edu/>) and DiscoTope2.0 tool (<http://www.cbs.dtu.dk/services/DiscoTope/>) were employed for the prediction of conformational

epitopes^{25,26}. While using BEpro residues with epitope score ≥ 1 were regarded as conformational B cell epitopes, a threshold of -3.7 was used for prediction by DiscoTope 2.0 server.

2.2 *In vitro* analysis of PfADI

2.2.1 Cloning of ADI and sequence analysis of *P. furukawaii* *arcA* gene:

The *arcA* gene coding for ADI enzyme in *P. furukawaii* cells was amplified by polymerase chain reaction (PCR). Primers (Forward primer- 5'ATATCCATGGCGATGTCCAAAGTCAAACCTCGG3' and reverse primer- 5'ATTACTCGAGGTAGTCGATCGGATCGCGG3') were designed and the PCR amplification was carried out using Phusion® (Thermo Scientific) and 2% DMSO in the MJ Mini thermal cycler (Bio-Rad). The reaction conditions were as follow: Initial denaturation at 98°C for 5 minutes followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 45 seconds, extension at 72°C for 45 seconds with a final extension at 72°C for 5 minutes.

The amplified fragment was cloned in pET-28a (+) vector at *NcoI*-*XhoI* restriction sites using standard cloning procedures. Fast digest *NcoI* and *XhoI* were obtained from Thermo Scientific (Waltham, MA, USA). The resultant recombinant plasmids were transformed in competent *E. coli* DH5α cells. Colony PCR was performed to screen the colonies with the construct. The positive clones were also confirmed by double digestion of the plasmid isolated from the colonies. The cloning was further confirmed by automated dideoxy DNA sequencing and subsequent homology search of the nucleotide sequence using nBLAST at NCBI (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

2.2.2 Expression of PfADI in heterologous host:

pET-*arcA* construct was transformed into *E. coli* BL21 cultured at 37 °C in Luria Bertani broth containing kanamycin (50 µg/mL). The induction conditions for the recombinant PfADI expression were optimized and performed with 1 mM isopropyl β-D-thio-galactopyranoside (IPTG) at O.D._{600nm} ~ 0.6. The induction was carried out for 6h. The expression of recombinant PfADI was checked on SDS-PAGE and later confirmed by western blotting.

2.2.3 Purification of recombinant PfADI:

Recombinant PfADI was over-expressed as inclusion bodies in the cytoplasm which was purified with the help of Ni²⁺-NTA affinity chromatography using the manufacturer's guidelines (Qiagen, Germany). The *E. coli* cells with induced recombinant PfADI were harvested and the pellet was dissolved in 8M urea and incubated at room temperature for 2-3 hours till the solution became clear, this step was followed by centrifugation. The pellet was discarded, and the supernatant was incubated with Ni²⁺-NTA slurry previously equilibrated with a lysis buffer overnight for binding. The bound slurry was passed through the column and the flow through was collected. On column renaturation of protein was performed by decreasing gradient of urea (8M to 0M). The purification steps following renaturation were carried out at

4°C. Later the protein was washed with 20mM and 40mM imidazole and eluted at 200 mM-500mM imidazole concentration in the elution buffer.

2.2.4 Enzyme Assay

In order to determine PfADI activity, the enzyme assay was performed using the method described by De Angelis and coworkers with certain modifications²⁷. The reaction mixture was prepared by adding 150 µl of purified recombinant PfADI into 150 µl of 50 mM substrate (L-arginine) and 1.85 ml of 50 mM acetate buffer. The mixture was then placed in a water bath at 37 °C for a duration of 1 h. The enzymatic reaction was stopped at the end of 1h by adding 2N HCl (500µl)). After the completion of the reaction, the mixture was centrifuged and 100µl of supernatant was taken for the next step i.e. color development. The development of color determines the amount of product (L-citrulline) formation. Color is developed using DAMO-TSC (diacetyl monoxime-thiosemicarbazide) method²⁸. In the color development step, 100µl of the previously mentioned supernatant was added in a test tube containing 2 ml acid-ferric solution and 1 ml of DAMO-TSC solution. The mixture was vortexed thoroughly and kept at 100 °C for 10 min. The developed color was analyzed using spectrophotometer by measuring absorbance at 520 nm. 1 U of ADI is defined as the amount of enzyme required to catalyze the conversion of one micro mole of substrate (L-arginine) into one micro mole of product (L-citrulline) in one minute under the standardized conditions. The amount of protein was quantified using Bradford's assay and the specific enzyme activity was evaluated.

2.2.5 Characterization of recombinant ADI from *P. furukawaii*

2.2.5.1 Effect of pH on the purified ADI

Effect of pH on the purified enzyme was used to determine optimum pH for ADI activity and pH stability of the enzyme. In order to determine the pH optima; ADI activity was calculated by the use of different buffers of 50mM concentration viz. acetate buffer (pH 5.5), citrate buffer (pH 4.3), potassium phosphate buffer (pH 7), Tris HCl (pH 8.8) in the reaction mixture. The highest ADI activity was set as 100% and relative activity was determined.

To observe the pH stability of the enzyme, ADI was pre-incubated in acetate buffer with the pH ranging from 4 to 8 at 4 °C for 12 hours. The residual enzyme activity at different pH was evaluated using standard assay conditions. All these experiments were carried out in triplicates and the average value was recorded.

2.2.5.2 Effect of temperature on ADI

The optimum temperature and the thermostability of the recombinant purified ADI was assessed. The optimum temperature was determined by incubating ADI with L-arginine in different temperatures (4°C - 100 °C). The ADI activity was calculated. Highest ADI activity was set as 100% and relative enzyme

activity was calculated. The thermostability of recombinant ADI was determined by incubating it at various temperatures (4 °C, 37 °C, 60 °C, 100 °C) for different time intervals.

2.2.5.3 Determination of kinetic parameters of recombinant PfADI

The kinetic parameters K_m and V_{max} of recombinant PfADI were evaluated using the Lineweaver-Burk plot. To calculate these parameters the enzyme activity was calculated in the presence of increasing substrate (L-arginine) concentration. The arginine concentration in the reaction mixture varied from 0.1 to 50 mM. Keeping the other conditions standard and uniform, the experiments were carried out in triplicates and mean value was used to plot the graph. The linear regression equation obtained from the double reciprocal plot was used to calculate the K_m and V_{max} values. The obtained regression equation was compared with the Michaelis–Menten equation.

2.2.6 Assessing *in vitro* anticancer activity of PfADI

Recombinant PfADI was tested for its anticancer activity on HCC cell lines HepG2. HepG2 cells were procured from ATCC. The cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (fetal bovine serum from invitrogen), 1% antibiotic solution (PenStrep from invitrogen) in 5% CO₂ atmosphere at 37 °C. Trypsin-EDTA solution was used to dissociate the cells. The previously cultured cells were adjusted to a cell count of 1.0×10^5 cells/ml using DMEM supplemented with 2% FBS. 1×10^4 cells/well were seeded in 96 well microtiter plate and was incubated for 24h for the formation of a partial monolayer of cells. Media was removed after 24 h and 100 µl of different concentrations of rPfADI was dispensed in the wells of the microtiter plates followed by an incubation for 72h at 37 °C in 5% CO₂ atmosphere. After 72 h, the recombinant PfADI solutions from each well was discarded and 100 µl of MTT solution was added. The plates were again incubated for 4 h. After incubation the supernatant was flicked off and 100 µl of DMSO was added to each well and a gentle shake was given to solubilize the formazan. The absorbance at 590 nm was determined using a microplate reader. The % growth inhibition was evaluated using the given formula and IC₅₀ value of recombinant PfADI for the inhibition of HepG2 cells was determined from the dose-response curve computed using GraphPad prism 9. Doxorubicin was used as the control drug.

$$\% \text{ Inhibition} = (\text{OD}_{590} \text{ of Control} - \text{OD}_{590} \text{ of sample}) / \text{OD}_{590} \text{ of Control} \times 100.$$

Results

3.1 *In silico* studies

3.1.1 Phylogenetic relatedness of PfADI

To assess the sequence-based relatedness of PfADI with ADIs of other *Pseudomonas* sp. (including those with proven anticancer activity), the neighbour-joining tree was constructed using retrieved ADI sequences (Table S1). Anticancer ADIs of *M. hominis* (MhADI) and *M. arginini* (MaADI) were taken as outgroup

species. The phylogenetic tree formed three major clusters (Fig 1) and interestingly, PfADI grouped into cluster I along with the two ADIs (of *P. aeruginosa*, *P. plecoglossicida*) with anticancer properties^{29–31}, thereby anticipating the anticancer potential of PfADI. Further, it may be worthwhile to investigate the ADI of the other related species in cluster I (*P. resinovorans*, *P. putida*, *P. citronellolis*) for potent anticancer activity.

[Fig 1 here]

3.1.2 Protein structure prediction of PfADI

The three-dimensional structure of PfADI, predicted using SWISS-MODEL server showed tetrameric subunits and the conserved catalytic triad (Glu 222, His 276, Cys 404) typical of prokaryotic ADIs (Fig 2). The template corresponding to the crystal structure of *P. aeruginosa* (PDB code_2ACI) which showed the highest similarity was used to build the model. Ramachandran favored residues for the predicted 3D structure of PfADI by homology modeling was 94.5% and MolProbity score was 1.56 (MolProbity version 4.4) indicating the robustness of the model (Fig. S1). The predicted 3D structure was further used for immunogenicity analysis.

3.1.3 Comparative immunoinformatics analysis of PfADI and MhADI

3.1.3.1 Prediction of overall antigenicity and allergenicity: Immunogenicity was predicted using VaxiJen server and the antigen probability score for PfADI was found to be less (0.3098) as compared to the predicted score for MhADI (0.4229) (Table 1). The comparison of the allergenicity showed a similar pattern as predicted by the amino acid composition based SVM module via AlgPred server. The PfADI was shown to be non-Allergen (Score=-1.15579) whereas MhADI was found to be an allergen with the allergenicity score -0.313383 at the threshold of -0.4.

[Table 1 here]

[Fig 2 here]

3.1.3.2 B cell epitope prediction: B cell epitopes were predicted to assess the intensity of humoral immune response against the enzyme. Linear B cell epitopes were predicted using BepiPred. A total of 13 linear epitopes of varied length were predicted (Table 2). The discontinuous or conformational epitopes were also predicted using DiscoTope 2.0 and BEpro servers. Five residues were predicted as conformational epitopes by DiscoTope 2.0 and BEpro identified 19 conformational epitopes (including the 5 predicted by DiscoTope 2.0). Thus, 19 residues out of the total 416 residues were recognized as conformational epitopes (Table 1). The B cell epitopes of MhADI were also analysed using the same tools. 15 linear and 32 conformational epitopes were predicted for MhADI³². The linear and conformational B cell epitopes of PfADI are listed in table 2. The various parameters like IEDB score, hydrophilicity and surface accessibility

are also mentioned in order to provide a quick reference for future mutagenesis studies for enzyme improvement.

[Table 2 here]

3.1.3.3 T cell epitope prediction: MHC-II binding T cell epitopes corresponding to the eight global alleles were predicted using IEDB server. The obtained data was used to calculate the relative frequency in order to estimate the epitope density. The epitope density for MhADI was also calculated in the similar manner. The T-cell epitope density was also low (0.0677) for PfADI as compared to MhADI (0.1044) (Table 1).

3.2 *In vitro* analysis of PfADI

3.2.1 Cloning of ADI and sequence analysis of *arcA*

A 1251 bp fragment of *arcA* gene coding for arginine deiminase was amplified from *P. furukawaii* genome. The gene product was purified and ligated into pET28a vectors and was transformed into competent *E. coli* DH5α cells. Colony PCR was performed to screen the transformants, the gene of interest was observed in all the positive clones. Restriction digestion of the plasmid isolated from the colony PCR positive clones with *NcoI-XhoI* enzymes further confirmed cloning of *arcA* in pET28a (+) as a fall out was observed at 1251 bp along with the linearized vector backbone of 5.4 kbp. The clones were further verified by automated DNA sequencing and the sequence is submitted in Genbank under accession no. MK318561.

Homology search of cloned *arcA* gene showed 100% identity with annotated *arcA* gene present in complete genome sequence of *P. furukawaii* (Accession No. AP014862.1). Consequently, the *in silico* translated sequence of cloned *arcA* gene also revealed 100% identity with ADI of *P. furukawaii* (Accession No. BAU77093), which had been used for phylogenetic analysis and homology modeling.

3.2.2 Expression and purification of recombinant PfADI

The pET-*arcA* construct was transformed into a competent expression host *E. coli* BL21 (DE3). The transformants were successfully induced using 1mM IPTG and the induced protein was visualized on SDS-PAGE. The PfADI was over-expressed in *E. coli* under the control of strong T7 promoter as inclusion bodies. The recombinant PfADI was purified from inclusion bodies using Ni²⁺-NTA affinity chromatography. The purified ADI protein fractionated on 12% SDS-PAGE and was observed as single band at ~46 kDa (Fig 3). The recombinant PfADI was purified with a specific enzyme activity of 1.9 IU/ml. Western blotting was done to confirm the presence of His-tagged recombinant ADI using anti-histidine antibodies. A specific band at ~46kda was observed in the induced sample (Fig S2).

[Fig 3 here]

3.2.3 Characterization of purified recombinant ADI

3.2.3.1 Effect of pH: Different buffers viz. citrate buffer, acetate buffer, phosphate buffer and Tris-HCl of pH range 4-8 were used to assess the effect of pH on ADI activity of purified recombinant protein. The highest ADI activity was observed at pH 6 which was marked 100% and the relative activity at other pH were calculated. As shown in Fig 4 A, 96% of the activity was retained at pH 7. The enzyme activity dropped to 75% at pH 8.

To study the pH stability, purified ADI was pre-incubated with different buffers of pH range 4 to 8 for 12 h and the residual activity was checked. The enzyme activity was almost negligible after pre-incubation at pH 4 and pH 8 (Fig. 4 B). However, the enzyme was stable at pH 6 and 7. Thus the optimum pH for recombinant *P. furukawaii* ADI is 6 and the enzyme was highly stable in the pH range 6-7.

3.2.3.2 Effect of temperature: Both the optimum temperature and thermal stability of ADI at different temperatures were analysed. The ADI showed highest activity at 37 °C, 91% of the enzyme activity was observed at 60 °C. The activity increased linearly from 4 °C to 20 °C. 33% enzyme activity was obtained when the enzyme was incubated at 100 °C (Fig 4 C).

The thermal stability of ADI was estimated at different temperatures for different time intervals. The enzyme was stable at 4 °C and 37 °C throughout the experiment. At 60 °C, the enzyme activity decreased after 2h of incubation. The enzyme lost all the activity after 90 mins at 100 °C (Fig 4 D). Thus, the enzyme is stable over a wide temperature range with maximum activity at human physiological temperature.

[Fig 4 here]

3.2.3.3 Kinetic parameters of recombinant ADI: The K_m and V_{max} value of the purified recombinant PfADI were determined by calculating the enzyme activity of ADI with increasing concentration of the substrate L-arginine (0.1 to 50 mM). The Lineweaver burk plot was plotted using 1/S and I/V values (Fig S3). The K_m and V_{max} value as calculated using the Michaelis–Menten equation were 1.90 mM and 1.83 $\mu\text{mol/ml/min}$ respectively.

3.2.3.4 *In vitro* anticancer activity: The growth inhibitory effect of recombinant PfADI was tested *in vitro* on HepG2 cells. The anti-proliferative activity was evident by microscopic examination. HepG2 cells were treated with recombinant PfADI in a dose dependent manner. MTT assay was performed and IC_{50} value was determined based on sigmoidal dose response curve. Recombinant PfADI showed IC_{50} value of

0.1950 IU/ml equivalent to 0.007 µg/ml (Fig 5) against HepG2 cells whereas the standard Doxorubicin (drug control) showed an IC₅₀ value of 18.71µM.

[Fig 5 here]

Discussion

The present study was undertaken to determine the potential of recombinant L-arginine deiminase from *P. furukawaii* as an anticancer agent. Previously, we have screened 143 ADI producing isolates from pond water and soil samples from different districts of Haryana and Delhi, India. Isolate RS3 which was identified as *P. furukawaii* showed maximum activity at physiological pH and temperature and it was chosen for further studies¹⁵. In the current study, computational tools were employed to reveal the structure of PfADI and to predict immunogenic properties. Sequence based phylogenetic analysis was carried out to investigate the relatedness between PfADI and ADIs from other organisms with known anticancer potential. The sequence-structure based immunogenic properties of PfADI were also compared with the ADI currently in the clinical trial (MhADI) to evaluate its suitability for ADI based therapeutics. Further, *arcA* gene coding for PfADI was cloned in *E. coli* with the aim to enhance and ease the production and purification of ADI for assessing its anticancer activity. The purified enzyme was characterized.

Primarily, the phylogenetic analysis was performed to assess the relatedness of PfADI with ADIs of other species of *Pseudomonas* genera with established anticancer activities. It was interesting to observe that PfADI clustered with ADI of *P. aeruginosa* and *P. plecoglossicida* (which have been previously cloned and expressed in *E. coli* and have proven anticancer activity *in vitro*)^{29–31} and thus encouraged further analysis. Immunogenicity and allergenicity are the major problems associated with the protein therapeutics. Thus, for the development of PfADI as a therapeutic protein assessing its immunogenicity is an important prerequisite. In the present study we used immunoinformatics approach to analyse the antigenicity and allergenicity of the PfADI and compared it to MhADI which is under phase III clinical trials. In contrast to the time consuming and expensive experimental techniques, bioinformatics offer many algorithms which are in public domain and are highly preferred for the immunogenic and allergenic predictions³³. Previously, other therapeutic enzymes like asparaginase and uricase were subject to immunoinformatics analysis and the results are in line with the experimental observations^{34,35}. In the present study, the antigenicity of PfADI was found to be less than MhADI using several prediction softwares. *In silico* analysis for allergenicity prediction showed PfADI as a non-allergen and thus suitable to be used as protein therapeutics.

The linear and conformational B cell epitopes were also predicted for both the ADIs. B cell epitopes represent the precise region of the protein where the paratope of the antibodies generated by the host immune system binds. In the present study it was observed that there are fewer B cell epitopes in PfADI

as compared to MhADI. This observation indicates that there is less probability of interaction between PfADI and antibodies as compared to MhADI, hence PfADI is expected to be more stable in the human host.

Another measure of host immunogenic reaction is estimating the T-cell epitope density. The experimental reports on different proteins have confirmed that the response of the immune system is directly proportional to the epitope density^{35,36}. Thus, a higher T cell epitope density of MhADI with respect to MHC-II binding molecules indicates a high rate of immunogenic reaction in comparison to PfADI. Hence the preliminary analysis suggests that the PfADI is superior to the ADI in the clinical trials as it is low immunogenic and non-allergic. Thus, with further investigation and detailed study PfADI could be developed as a suitable alternative to the MhADI, similar to the *Erwinia chrysanthemi* asparaginase which was discovered as an alternative to the commonly used *E. coli* asparaginase, as some patients were found to develop allergic reaction against the latter³⁷.

After the *in silico* predictions, *in vitro* efficacy of PfADI as a potential anticancer drug candidate was validated, the *arcA* gene of PfADI was cloned and expressed in *E. coli*. Previously, ADI from various organisms viz *Streptococcus sanguis*, *Lactococcus lactis*, *Enterococcus faecalis*, *M. arginini* have been cloned and over-expressed in *E. coli*^{3,38–40} with diverse aims such as to understand its importance in cell growth, arginine metabolism or the role as anticancer candidate⁴¹. The *arcA* gene from two species of genus *Pseudomonas* namely *P. aeruginosa* and *P. plecoglossicida* have also been cloned in the *E. coli* host^{31,42}. As compared to the 1251 bp *arcA* gene in the present study of *P. furukawaii*, the *arcA* gene in *Enterococcus faecalis* and *Lactococcus lactis* are 1260 and 1399 bp long respectively while in *P. plecoglossicida* CGMCC2039 is 1,254-bp fragment long. The *arcA* gene in *P. aeruginosa* is 1257 bp long and it codes for ADI composed of 418 amino acids.

The previously reported ADIs in other organisms contain almost similar numbers of amino acids ranging from 406 to 420 amino acids³. Our study was also in accordance with these findings and the *arcA* gene coding a protein of 416 amino acids was observed. However, the molecular weight of ADI differs significantly among different organisms due to the difference in oligomerization pattern of the various ADIs in their native form³. ADI of *M. arginini* exists as a homo-dimeric form with a molecular weight of 90 kDa whereas the 3-D structure analysis revealed that *P. aeruginosa* ADI folds into a homo-tetramer with a molecular weight of 184 kDa^{9,41}. In the present study ~46kDa band of purified recombinant PfADI band was observed on SDS-PAGE analysis.

The purified ADI was characterized and the optimum pH, temperature, pH stability, thermostability and kinetic parameters K_m and V_{max} were determined. The optimum pH and temperature of the PfADI were found to be 6 and 37 °C respectively. 96% of the enzyme activity was observed at pH 7. The enzyme also remained stable in the pH range 6-7 after 12 h of incubation. On assessing the thermostability, it was found that the enzyme was stable at 60 °C for 2 hours. All these features favor the role of ADI as anticancer modality. ADIs from other *Pseudomonas* species *P. putida* and *P. aeruginosa* have their pH

optima at 5.6 and 6.0-6.4 respectively ^{43,44}. The optimum pH varies from 5.0-7.2 for various bacterial species ³. The optimum temperature for *P. putida* and *S. pyogenes* ADI were also found to be 37 ° C ^{39,44}. However, the temperature optima for *E. faecalis* and *L. lactis* and *L. buchneri* were between 50-60 ° C ³⁸. The PfADI was stable from 4 to 40 ° C and retained 70% activity after two hours of incubation at 60 ° C. Thus, the PfADI is a thermostable robust enzyme with optimum activity at human physiological temperature and pH. The K_m and V_{max} values of PfADI were calculated using Lineweaver-Burk plot and were found to be 1.90 mM and 1.83 $\mu\text{mol/ml/min}$ respectively. K_m determines the affinity of an enzyme to the substrate. The low K_m value signifies high affinity and vice versa. The K_m value for different ADIs varied in the range 0.14-10.1 ^{9,45}. The source of ADI, environmental and cultural conditions have a role in determining the K_m and V_{max} of any enzyme. The difference in kinetic parameters of similar proteins may be attributed to the sensitivity of the enzyme assay and purity of the enzyme ⁴⁴.

After the expression and purification, the *in vitro* anticancer efficacy of recombinant PfADI was tested *in vitro* against HCC cell lines, HepG2. The PfADI exhibited significant anti-proliferation activity against the tested cell lines with IC_{50} value of 0.1950 IU/ml corresponding to a protein concentration of 0.007 $\mu\text{g/ml}$. Ensor and coworkers ⁴⁶ have earlier tested the *in vitro* anticancer activity of rMhADI against 23 melanoma and 16 HCC cell lines. All the cell lines were sensitive towards ADI treatment. The 50% growth inhibition of melanoma cell lines was observed in the concentration range of 0.01 $\mu\text{g/ml}$ to 0.3 $\mu\text{g/ml}$, whereas the IC_{50} value for HCC cell lines varied from 0.03 $\mu\text{g/ml}$ to less than 0.01 $\mu\text{g/ml}$. The inhibition of HepG2 was observed at IC_{50} value of 0.01 $\mu\text{g/ml}$ ⁴⁶. Thus *in vitro* anticancer efficacy of PfADI (IC_{50} 0.007 $\mu\text{g/ml}$) was found to be better as compared to with MhADI activity (IC_{50} 0.01 $\mu\text{g/ml}$) against the HCC cell line HepG2. However, the experimental conditions and the cell viability assays were different in the two experiments. Previously, partially purified ADI of *P. plecoglossicida* was also used to inhibit growth of HepG2 cell lines. ADI activity of 0.05 U/ml inhibited the growth of HepG2 cells by 60% whereas 93.4% inhibition rate was observed by 0.5 U/ml ADI ³⁰. In another study, *in vitro* efficacy of recombinant ADI from *M. hominis* showed an IC_{50} value of 0.036 U/ml on melanoma cell lines G-361 ⁴⁷.

It is important to mention here that the rate of inhibition of the cancer cell lines differs not only because of the source of the enzyme but also it differs with different types of cancers ⁴⁸. Further, the inhibitory activity of the same enzyme also varies for the different cell lines of the same type of cancer ⁴⁸. Such observation is because of the discrepancy in the expression of enzyme argininosuccinate synthase. As mentioned earlier, the absence of ASS1 is the hallmark for arginine auxotrophy. McAlpine et. al performed the western blot of ASS1 protein in various HCC cell lines in order to understand the different level of ASS1 expression in these cell lines ⁴⁸. The study designated all the cell lines as ASS1 high, medium, low or negative depending on the level of ASS1 expression. HepG2 cell lines are found to express medium levels of ASS enzyme. The recombinant PfADI showed significant activity against a medium level ASS1 expressing cell line (HepG2), and thus is expected to show even better results with low or nil ASS1 expressing tumors. Hence, extensive studies are required to explore a spectrum of cancer types with low or nil ASS1 levels that can be targeted via AADT using ADI.

In conclusion, we have obtained a recombinant ADI from *P. furukawaii* which can be a promising anti-tumor agent in arginine deprivation therapy for cancer treatment. This novel PfADI is predicted to offer lower immunogenicity and allergenicity as compared to the MhADI which is in the clinical trials. The enzyme is also stable at physiological pH and temperature and can be further developed as an anticancer modality. PfADI can not only act as an alternative to MhADI, its consecutive administration along with MhADI might help in reducing the immunogenic response due to the variable antigenic properties of both the enzymes. Further, our *in silico* predictions of the T cell and B cell epitopes of ADI from *P. furukawaii* can provide a framework for designing mutagenesis experiments in order to deimmunize the protein further.

Declarations

Acknowledgments: The authors are thankful to the Department of science and technology (DST), Government of India for financially supporting the study (SB/YS/LS-145/2014). The authors are also grateful to DST-FIST grant (1196 SR/FST/LS-I/2017/4) and Department of Biotechnology, Ministry of Science and Technology, BTISNET program grant [BT/BI/25/059/2012-BIF] for providing the infrastructure facility. RD expresses her gratitude to DST and MDU for providing the research fellowship. The authors sincerely thank and acknowledge Prof. Rakesh Bhatnagar for allowing us to carry out a part of this study in his laboratory at Jawaharlal Nehru University, New Delhi.

Funding: This study was funded by the Department of Science and Technology (DST), Government of India (SB/YS/LS-145/2014).

Conflict of interest: The authors declare they have no conflict of interests.

Data availability statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Author contribution statement: PG, RD, VG and AM conceived and planned the experiments. RD and VG performed the experiments. PG supervised the project and received the funding. RD wrote the manuscript. AM did the supervision of bioinformatics investigation. AK helped in bioinformatics studies. PG, AK, AM and VG did the reviewing and editing.

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Dhankhar R, Gupta V, Kumar S, Kapoor RK, Gulati P. Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment. *Appl Microbiol Biotechnol*. 2020;104(7):2857-2869. doi:10.1007/s00253-020-10432-2
2. Han RZ, Xu GC, Dong JJ, Ni Y. Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug. *Appl Microbiol Biotechnol*. 2016;100(11):4747-4760. doi:10.1007/s00253-016-7490-z
3. Maneerat K, Yongkiettrakul S, Jiemsup S, Tongtawe P, Gottschalk M, Srimanote P. Expression and characterization of serotype 2 *Streptococcus suis* arginine deiminase. *Microb Physiol*. 2017;27(3):133-146. doi:10.1159/000452952
4. Zúñiga M, Pérez G, González-Candelas F. Evolution of arginine deiminase (ADI) pathway genes. *Mol Phylogenet Evol*. 2002;25(3):429-444. doi:10.1016/S1055-7903(02)00277-4
5. Dhankhar R, Gulati P, Kumar S, Kapoor RK. Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape. *Expert Opin Ther Pat*. 2018;28(8):603-614. doi:10.1080/13543776.2018.1508452
6. Riess C, Shokraie F, Classen CF, et al. Arginine-depleting enzymes – an increasingly recognized treatment strategy for therapy-refractory malignancies. *Cell Physiol Biochem*. 2018;51(2):854-870. doi:10.1159/000495382
7. Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. *Oncogene*. 2016;35(38):4957-4972. doi:10.1038/onc.2016.37
8. Shen LJ, Beloussow K, Shen WC. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. *Cancer Lett*. 2006;231(1):30-35. doi:10.1016/j.canlet.2005.01.007
9. Kawatra A, Dhankhar R, Gulati P. Microbial arginine deiminase: a multifaceted green catalyst in biomedical sciences. *Int J Biol Macromol*. 2022;196:151-162. doi:10.1016/j.ijbiomac.2021.12.015
10. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. *Oncotarget*. 2010;1(4):246-251. Accessed January 4, 2022. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998341/>
11. Abou-Alfa GK, Qin S, Ryoo BY, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. *Ann Oncol*. 2018;29(6):1402-1408. doi:10.1093/annonc/mdy101
12. Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. *Br J Cancer*. 2010;103(7):954-960. doi:10.1038/sj.bjc.6605856

13. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. *Cancer*. 2007;110(1):103-111. doi:10.1002/cncr.22739
14. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. *Adv Drug Deliv Rev*. 2008;60(1):59-68. doi:10.1016/j.addr.2007.06.011
15. Dhankhar R, Kumar A, Kumar S, Chhabra D, Shukla P, Gulati P. Multilevel algorithms and evolutionary hybrid tools for enhanced production of arginine deiminase from *Pseudomonas furukawaii* RS3. *Bioresour Technol*. 2019;290:121789. doi:10.1016/j.biortech.2019.121789
16. Kimura N, Watanabe T, Suenaga H, et al. *Pseudomonas furukawaii* sp. nov., a polychlorinated biphenyl-degrading bacterium isolated from biphenyl-contaminated soil in Japan. *Int J Syst Evol Microbiol*. 2018;68(5):1429-1435. doi:10.1099/ijsem.0.002670
17. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol Biol Evol*. 1987;4(4):406-425. doi:10.1093/oxfordjournals.molbev.a040454
18. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. *Mol Biol Evol*. 2018;35(6):1547-1549. doi:10.1093/molbev/msy096
19. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. *Evol Int J Org Evol*. 1985;39(4):783-791. doi:10.1111/j.1558-5646.1985.tb00420.x
20. Nei M, Kumar S. *Molecular Evolution and Phylogenetics*. Oxford University Press; 2000.
21. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC Bioinformatics*. 2007;8(1):4. doi:10.1186/1471-2105-8-4
22. Saha S, Raghava GPS. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. *Nucleic Acids Res*. 2006;34(suppl_2):W202-W209. doi:10.1093/nar/gkl343
23. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. *Nucleic Acids Res*. 2011;39(suppl_1):D913-D919. doi:10.1093/nar/gkq1128
24. Southwood S, Sidney J, Kondo A, et al. Several common hla-dr types share largely overlapping peptide binding repertoires. *J Immunol*. 1998;160(7):3363-3373. Accessed January 4, 2022. <https://www.jimmunol.org/content/160/7/3363>
25. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. *PLOS Comput Biol*. 2012;8(12):e1002829. doi:10.1371/journal.pcbi.1002829

26. Sweredoski MJ, Baldi P. PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. *Bioinformatics*. 2008;24(12):1459-1460. doi:10.1093/bioinformatics/btn199
27. Angelis MD, Mariotti L, Rossi J, et al. Arginine catabolism by sourdough lactic acid bacteria: purification and characterization of the arginine deiminase pathway enzymes from *Lactobacillus sanfranciscensis* CB1. *Appl Environ Microbiol*. Published online December 2002. doi:10.1128/AEM.68.12.6193-6201.2002
28. Qian J, Sun Z, Liu Y, Meng F, Liu Y. Determination of L-citrulline in enzymatic conversion solution by diacetylmonoxime-thiosemicarbazide colorimetry. *Chin. J. Pharm*. 2007;38:519–522.
29. Bala K, Husain I, Sharma A. Arginine deaminase from *Pseudomonas aeruginosa* PS2: purification, biochemical characterization and in-vitro evaluation of anticancer activity. *3 Biotech*. 2020;10(5):226. doi:10.1007/s13205-020-02212-6
30. Liu YM, Sun ZH, Ni Y, Zheng P, Liu YP, Meng FJ. Isolation and identification of an arginine deiminase producing strain *Pseudomonas plecoglossicida* CGMCC2039. *World J Microbiol Biotechnol*. 2008;24(10):2213-2219. doi:10.1007/s11274-008-9732-4
31. Ni Y, Li Z, Sun Z, et al. Expression of arginine deiminase from *Pseudomonas plecoglossicida* CGMCC2039 in *Escherichia coli* and its anti-tumor activity. *Curr Microbiol*. 2009;58(6):593-598. doi:10.1007/s00284-009-9376-0
32. Zarei M, Nezafat N, Rahbar MR, et al. Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis. *J Biomol Struct Dyn*. 2019;37(2):523-536. doi:10.1080/07391102.2018.1431151
33. Evander Emeltan Tjoa S, Maria Vianney Y, Emantoko Dwi Putra S. *In silico* mutagenesis: decreasing the immunogenicity of botulinum toxin type A. *J Biomol Struct Dyn*. 2019;37(18):4767-4778. doi:10.1080/07391102.2018.1559100
34. Belén LH, Lissabet JB, de Oliveira Rangel-Yagui C, et al. A structural *in silico* analysis of the immunogenicity of L-asparaginase from *Escherichia coli* and *Erwinia carotovora*. *Biologicals*. 2019;59:47-55. doi:10.1016/j.biologicals.2019.03.003
35. Tripathi S, Parmar J, Kumar A. Structure-based immunogenicity prediction of uricase from fungal (*Aspergillus flavus*), bacterial (*Bacillus subtilis*) and mammalian sources using immunoinformatic approach. *Protein J*. 2020;39(2):133-144. doi:10.1007/s10930-020-09886-0
36. Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen YH. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. *Vaccine*. 2004;23(3):366-371. doi:10.1016/j.vaccine.2004.05.028

37. Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. *J Pharmacol Pharmacother*. 2016;7(2):62. doi:10.4103/0976-500X.184769
38. Jiang H, Huang K, Mu W, Jiang B, Zhang T. Characterization of a recombinant arginine deiminase from *Enterococcus faecalis* SK32.001 for L-citrulline production. *Process Biochem*. 2018;64:136-142. doi:10.1016/j.procbio.2017.06.006
39. Kim JE, Jeong DW, Lee HJ. Expression, purification, and characterization of arginine deiminase from *Lactococcus lactis* ssp. *lactis* ATCC 7962 in *Escherichia coli* BL21. *Protein Expr Purif*. 2007;53(1):9-15. doi:10.1016/j.pep.2006.12.002
40. Misawa S, Aoshima M, Takaku H, Matsumoto M, Hayashi H. High-level expression of *Mycoplasma* arginine deiminase in *Escherichia coli* and its efficient renaturation as an anti-tumor enzyme. *J Biotechnol*. 1994;36(2):145-155. doi:10.1016/0168-1656(94)90050-7
41. Ni Y, Schwaneberg U, Sun ZH. Arginine deiminase, a potential anti-tumor drug. *Cancer Lett*. 2008;261(1):1-11. doi:10.1016/j.canlet.2007.11.038
42. Oudjama Y, Tricot C, Stalon V, Wouters J. Overexpression, purification, crystallization and preliminary X-ray crystallographic analysis of *Pseudomonas aeruginosa* L-arginine deiminase. *Acta Crystallogr D Biol Crystallogr*. 2002;58(12):2150-2152. doi:10.1107/S0907444902015743
43. Lu X, Li L, Wu R, et al. Kinetic analysis of *Pseudomonas aeruginosa* arginine deiminase mutants and alternate substrates provides insight into structural determinants of function. *Biochemistry*. 2006;45(4):1162-1172. doi:10.1021/bi051591e
44. Patil MD, Rathod VP, Bihade UR, Banerjee UC. Purification and characterization of arginine deiminase from *Pseudomonas putida*: structural insights of the differential affinities of L-arginine analogues. *J Biosci Bioeng*. 2019;127(2):129-137. doi:10.1016/j.jbiosc.2018.07.021
45. Ni Y, Liu Y, Schwaneberg U, et al. Rapid evolution of arginine deiminase for improved anti-tumor activity. *Appl Microbiol Biotechnol*. 2011;90(1):193-201. doi:10.1007/s00253-010-3051-z
46. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. *Cancer Res*. 2002;62(19):5443-5450.
47. Kozai M, Sasamori E, Fujihara M, Yamashita T, Taira H, Harasawa R. Growth inhibition of human melanoma cells by a recombinant arginine deiminase expressed in *Escherichia coli*. *J Vet Med Sci*. 2009;71(10):1343-1347. doi:10.1292/jvms.001343
48. McAlpine JA, Lu HT, Wu KC, Knowles SK, Thomson JA. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for

Tables

Table 1: Comparative immunoinformatics analysis of arginine deiminase from *P furukawaii* and *M hominis*

	Organism	Allergenicity*	Overall immunogenicity (VaxiJen score)	B cell epitope			T-cell epitope density
				Linear epitopes	Average IDEB Score	Conformational epitopes	
	<i>P furukawaii</i>	Non-Allergen Score=-1.1557941	0.3098	13	0.477	19	0.0677
	<i>M hominis</i>	Allergen Score=-0.31338318	0.4229	15	0.472	32	0.1044

*[Threshold=-0.4]

Table 2: Linear and Conformational B cell epitopes of PfADI.

Linear B cell epitopes					
Sr No.	Residue No	Epitope			
1	10-13	SEAG			
2	25-48	LAHTRLTPNNCDELLFDDVIWVSQ			
3	50-51	KR			
4	54	F			
5	79	Q			
6	81-86	KDALKW			
7	92-119	ITNDQVGVLVNEVRSWIEGLEPRKIAE			
8	122-155	IGGVAGSDLPESEGVSAIKMYRDYLGHSSFILPP			
9	180-184	WPARR			
10	196-219	FHPVFTGAEFEVWYGDPDKDHGMS			
11	296-322	VSEIVPFVLRPDESRPYGIDIRREEKD			
12	332-354	GLKQLRVVQTGGDAFEAEREQWD			
13	374-375	TY			
Conformational B cell epitopes					
Sr No.	Residue No	Residue	IEDB score	Hydrophilicity	Surface accessibility
1	62	E	0.291	2.814	1.153
2	81	K	0.059	2.557	1.85
3	111	G	0.224	-0.543	0.634
4	113	E	0.377	3.443	2.044
5	132	E	1.471	4.386	1.211
6	181	P	0.515	-0.5	2.358
7	213	D	1.95	6.514	4.68
8	214	K	1.896	6.514	2.773
9	215	D	1.724	4.486	1.775
10	216	H	1.383	5.114	1.424
11	217	G	0.955	4.429	1.028
12	307	D	1.11	3.657	5.49
13	308	E	1.262	5.271	4.334
14	309	S	1.74	4.4	4.392

15	310	R	1.418	4.914	2.603
16	311	P	1.448	2.343	1.053
17	320	E	-0.009	4.357	4.057
18	348	A	1.056	3.229	2.125
19	349	E	0.684	3.786	4.25

Figures

Figure 1

Phylogenetic tree based on Arginine deiminase sequences showing three clusters I, II and III. Red dots and Green triangles: ADI of *Pseudomonas* spp. and *Mycoplasma* spp. with demonstrated anticancer activity.

Figure 2

Homology model of Arginine deiminase of *Pseudomonas furukawaii* showing (A) the tetrameric subunits; (B) conserved catalytic triad (Cys-His-Glu)

Figure 3

Purification of recombinant PfADI. SDS-PAGE gel showing purification of protein from inclusion bodies (M- protein marker, UI- uninduced, I- induced, CT- cytoplasmic, MB- membrane bound, IB- inclusion bodies. FT- flow through, W -wash, E2-E5- elutions).

A **B**

Figure 4

Effect of pH and temperature on purified recombinant PfADI. A. Optimum pH for ADI activity. B. pH stability of ADI. C. Optimum temperature for ADI activity. B. Thermal stability of ADI at different temperatures.

A

B

Figure 5

Dose response curve for the inhibitory action of PfADI on HepG2 cells

Figure 6

Legend not provided with this version.

Figure 7

Legend not provided with this version.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarydata1.docx](#)